Type 2 immunity-driven diseases: Towards a multidisciplinary approach.

Authors:
Hassoun D; Malard O; Barbarot S; Magnan A; Colas L.

Journal:
Clin Exp Allergy

Publication Year: 2021

DOI:
10.1111/cea.14029

PMCID:
PMC9292742

PMID:
34617355

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Exp Allergy

Abbreviation: Clin Exp Allergy

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Anaphylaxis in Brazil between 2011 and 2019.
Tanno LK; Molinari N; Annesi-Maesano I and 2 more (2022) - Transparency Score: 3/6
Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with na…
Eide JG; Wu J; Stevens WW and 16 more (2022) - Transparency Score: 3/6
Association between allergic sensitization and intestinal parasite infection in schoolchildren in G…
Brandt O; Wegenstein B; Müller I and 12 more (2022) - Transparency Score: 3/6
Burden of allergic disease among ethnic minority groups in high-income countries.
Jones CJ; Paudyal P; West RM and 5 more (2022) - Transparency Score: 2/6
Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctiv…
de Blay F; Gherasim A; Domis N and 2 more (2022) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTERESTS DH declares the following conflict of interest: Support for attending meetings and/or travel from SANOFI, Novartis, GSK and AstraZeneca. OM declares the following link of interest: Adviser, and/or clinical study investigator for Medtronic, Sanofi‐Genzyme, GSK, Novartis, MSD, ALK. SB declares the following conflict of interest: Scientific adviser, consultant, and/or clinical study investigator for Almirall, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo‐Pharma, Pfizer, Eli Lilly, UCB Pharma. AM declares the following conflict of interest: Consultant or investigator for Novartis, GSK, SANOFI & Astra Zeneca. LC declares the following link of interest: Support for a PhD."

Evidence found in paper:

"Funding information"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025